BOLAR MAKES UP LOST GROUND WHILE INDEX REMAINS FLAT PRIOR TO LABOR DAY
Bolar (up 3-3/8 to 16-1/2) quickly rebounded from its nearly five-point setback two weeks ago by turning in the best gain on the "F-D-C" Index during the week ended Aug. 30. The stock's 26% price increase in five days came on the heels of an announcement that the company would comply with FDA wishes by shipping previously reformulated generic products in their original NDA-approved formulations ("The Pink Sheet" Aug. 26, p. 3). Alza (up 2-1/4 to 24-1/4) was the only other major gainer among the Pharmaceuticals during a sluggish trading week for Indes issues and for Wall Street in general. Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth